Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications

Saeki, Yukihiko; Mima, Toru; Ishii, Taeko; Ogata, Atsushi; Kobayashi, Hideyuki; Ohshima, Shiro; Ishida, Tomohiro; Tabunoki, Yuichiro; Kitayama, Hitoshi; Mizuki, Masao; Katada, Yoshinori; Asaoku, Hideki; Kitano, Masayasu; Nishimoto, Norihiro; Yoshizaki, Kazuyuki; Maeda, Masahiro; Kawa, Shigeyuki; Kinoshita, Naokazu; Uede, Toshimitsu; Kawase, Ichiro

doi:10.1046/j.1365-2141.2003.04589.x

Cited by 56 publications

(16 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding agrees with some [25, 26], but not all, investigations [20, 27]. Furthermore, Saeki et al, Scudla et al, and Minarik et al have observed differences in plasma OPN levels between monoclonal gammopathy of undetermined significance and MM [26, 28–30].…”

Section: Discussionsupporting

confidence: 91%

Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma

Valković

Babarović

Lučin

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

The aim of this pilot study was to determine the plasma levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF) and find possible association between them and main clinical features and parameters of tumor burden in patient with multiple myeloma (MM). Plasma levels of OPN and VEGF were determined in 44 newly diagnosed MM patients and 24 healthy persons by ELISA method. These values were compared with the presence of anemia, renal dysfunction, and bone lesions as myeloma related clinical manifestations and with serum beta-2 microglobulin and Durie-Salmon clinical stage as prognosticators related to tumor mass. The value of OPN was significantly higher in MM patients with evident bone lesions (P = 0.03) and there was also a positive correlation with serum beta-2 microglobulin (r = 0.366; P = 0.04). Furthermore, patients with lower Durie-Salmon stage had significantly lower OPN and VEGF levels (P = 0.05; P = 0.04, resp.). Our preliminary results found positive association between plasma level of OPN, tumor burden, and bone destruction. Further analysis should provide information about the possible use of OPN as useful clinical biomarker for monitoring bone disease and tumor mass, as well as a prognostic factor, or a possible target for pharmacological intervention.

show abstract

Section: Discussionsupporting

confidence: 91%

Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma

Valković

Babarović

Lučin

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The association between OPN and solid cancers has been reported in hepatocellular carcinoma, pancreatic Cancer and lung cancer [20,21,22]. Increased serum OPN concentrations occur in chronic myeloid leukemia, multiple myeloma, and acute myeloid leukemia [23]. Higher OPN were associated with significant shorter survival times in AML patients in a 1-year survival analysis [24].…”

Section: Discussionmentioning

confidence: 99%

The OPN Gene Polymorphism Confers the Susceptibility and Response to Ara-C Based Chemotherapy in Chinese AML Patients

Zhang¹,

Yang²,

Li³

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Aim: To investigate the possible association between the Osteopontin (OPN) gene polymorphisms and the susceptibility and chemotherapy response of acute myeloid leukemia patients. Methods: A total of 381 patients with de nova AML and 430 healthy controls were enrolled. All patients received Ara-C-based standard induction chemotherapy regimens, and the treatment response was evaluated. Several polymorphisms in the human OPN encoding gene have been identified. The OPN) gene polymorphisms at 3 loci, namely, -156 GG>G, -443 C>T and -66T>G were determined. Results: We identified that the -443C>T polymorphism was the only one which is closely related to AML. Compared with the -443TT carriers, our data showed that the -443CC genotype carriers were significantly related to a higher risk for AML. The -443CC genotype was also more prevalent in poor response groups than in good response group. The -443CC carriers are more likely to have poor response to AML treatment. Cellular assay indicated that the leukemic cell lines receiving the OPN -443C transfection have a significantly lower apoptosis rate to Ara-C treatment compared to cell lines transfected with -443T. Conclusion: The findings of this study suggest OPN-443C>T gene polymorphism may be sued as a molecular for susceptibility and chemotherapy response of AML.

show abstract

“…In one study, OPN from bone marrow derived cells enhanced migration of MCF-7 breast cancer cells in a Transwell co-culture system [71]. Bone marrow cells in overt myeloma patients produce more OPN than myeloma precursor disease [72]. In addition, myeloma cells express and bind to OPN [72, 73].…”

Section: Small Integrin-binding Ligand N-linked Glycoproteins (Siblings)mentioning

confidence: 99%

“…Bone marrow cells in overt myeloma patients produce more OPN than myeloma precursor disease [72]. In addition, myeloma cells express and bind to OPN [72, 73]. Plasma OPN levels in myeloma patients positively correlate with disease progression, bone destruction and angiogenesis [74].…”

Section: Small Integrin-binding Ligand N-linked Glycoproteins (Siblings)mentioning

confidence: 99%

Matricellular proteins as regulators of cancer metastasis to bone

Trotter

Yang

2016

Matrix Biology

View full text Add to dashboard Cite

Metastasis is the major cause of the death in cancer patients, and a frequent site of metastasis for many cancers is the bone marrow. Therefore, understanding the mechanisms underlying the metastatic process is necessary for future prevention and treatment. The tumor microenvironment is now known to play a role in the metastatic cascade, both at the primary tumor and in metastatic sites, and includes both cellular and non-cellular components. The extracellular matrix (ECM) provides structural support and signaling cues to cells. One particular group of molecules associated with the ECM, known as matricellular proteins, modulate multiple aspects of tumor biology, including growth, migration, invasion, angiogenesis and metastasis. These proteins are also important for normal function in the bone by regulating bone formation and bone resorption. Recent studies have described a link between some of these proteins and metastasis of various tumors to the bone. The aim of this review is to summarize what is currently known about matricellular protein influence on bone metastasis. Particular attention to the contribution of both tumor cells and non-malignant cells in the bone has been given.

show abstract

Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications

Cited by 56 publications

References 43 publications

Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma

Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma

The OPN Gene Polymorphism Confers the Susceptibility and Response to Ara-C Based Chemotherapy in Chinese AML Patients

Matricellular proteins as regulators of cancer metastasis to bone

Contact Info

Product

Resources

About